BeOne Medicines Agrees To Sell Its Royalty Rights On The Worldwide Sales, Excluding China, Of Amgen's Imdelltra (Tarlatamab-dlle) For Up To $950M To Royalty Pharma

Author: Benzinga Newsdesk | August 25, 2025 05:07am

• Under the terms of the agreement, BeOne will receive an upfront payment of $885 million, with the option to sell remaining royalties within 12 months for up to $65 million. BeOne will share in a portion of the royalty on annual sales above $1.5 billion, and will maintain royalty and all other rights to other assets under the terms of the existing collaboration with Amgen, including xaluritamig, a first-in-class STEAP1 x CD3 XmAb currently being studied in patients with metastatic castration-resistant prostate cancer (mCRPC).
• Royalty Pharma to acquire rights to BeOne's royalties on IMDELLTRA® (tarlatamab-dlle) worldwide (ex-China) sales for up to $950 million
• IMDELLTRA is a first-in-class DLL-3 targeting bispecific T-cell engager, indicated for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy

Posted In: AMGN ONC RPRX